(NASDAQ: SGMO) Sangamo Therapeutics's forecast annual revenue growth rate of 9.48% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.17%.
Sangamo Therapeutics's revenue in 2025 is $81,706,000.On average, 8 Wall Street analysts forecast SGMO's revenue for 2025 to be $22,403,739,518, with the lowest SGMO revenue forecast at $10,259,932,747, and the highest SGMO revenue forecast at $39,505,839,966. On average, 8 Wall Street analysts forecast SGMO's revenue for 2026 to be $18,428,717,053, with the lowest SGMO revenue forecast at $2,542,807,540, and the highest SGMO revenue forecast at $37,381,805,192.
In 2027, SGMO is forecast to generate $36,437,454,503 in revenue, with the lowest revenue forecast at $5,913,505,906 and the highest revenue forecast at $82,873,561,340.